chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On 4th day after vaccination, experienced dizziness and very low blood pressure. Normal Blood pressure is around 112/65. Blood pressure during the dizziness event (today) was measured as 97/62. I suffer from Hypertension and take Amlodipine Besylate 10 mg/day, which lowers the BP to normal. I have continued to take the Amlodipine Besylate after vaccination.  I have not has any additional adverse side effects from the vaccination.  Seven hours after the  vaccination on February 4th, blood pressure was measured as 105/61.  On Feb 5th, the BP was measure at 122/72.  On Feb 7th, the BP was measured at 101/63.  The day (February 9th) started with extreme fatigue and the feeling of not having slept well (I had 9.5 hours of sleep).  No other symptoms except the dizziness. SPO2 measured at 98/99 % and PI was 5.4. RR was 19/minute. Oral temperature has been normal at 98.0 (normal for me).
Message from CDC and spoke to someone - if the injection was given between the 4th or 5th dose of Dtap it is counted as a Dtap and does not need to worry about other effects and can continue the series.
pt states that she developed chills, severe headache and vomiting for a day and a half.  She continues to have a headache.  She has been taking Tylenol, aspirin, ibuprofen, alka seltzer.  Pt will contact her PCP regarding her symptoms.
In the first 24 hours airway swelling, respiratory distress, rash diffuse macule papular, severe exacerbation of asthma (less than 24 hrs) requiring extensive use of steroids for control of allergic exacerbation. Continued less than 50 mg prednisone 2 months over months causing adrenal insufficiency now tapering off. The event was the second reaction after or to a vaccine within 6 months prior event to FLUZONE occurred in Jan 2015. This event was to PREVNAR but was similar with rash, respiratory distress exacerbation of asthma and allergies requiring prolonged use of high dose steroid as symptoms and sign of respiratory issues occurred but needed to continue prednisone due to adrenal insufficiency or failure on attempts to withdrawal steroid with cortisol approximately 1.
Headache; Body aches; Chills; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), PAIN (Body aches) and CHILLS (Chills) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 15-Mar-2021, the patient experienced HEADACHE (Headache), PAIN (Body aches) and CHILLS (Chills). At the time of the report, HEADACHE (Headache), PAIN (Body aches) and CHILLS (Chills) outcome was unknown.            Concomitant medications were not reported Treatment information were not provided Action taken with mRNA-1273 in response to the event was not applicable
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (soreness at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The patient's past medical history included No adverse event (No relevant medical history reported). On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Jan-2021, the patient experienced VACCINATION SITE PAIN (soreness at injection site). At the time of the report, VACCINATION SITE PAIN (soreness at injection site) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Treatment and medication drugs were not provided by reporter. Reporter did not allow further contact.
Patient has injection site reaction - a little itching and redness without a bump at injection site approximately size of a silver dollar (per patient conversation via phone) no other symptoms.
Patient was administer bivalent dose in error.   He still needs to complete the primary series.
died from heart attacks; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MYOCARDIAL INFARCTION (death, medically significant), outcome "fatal", described as "died from heart attacks". The patient date of death was unknown. Reported cause of death: "died form heart attacks". It was not reported if an autopsy was performed.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300112857 same reporter, product, event; different patient;; Reported Cause(s) of Death: died form heart attacks
74-y/o female patient with a history of hypertension colon cancer thalassemia hyperlipidemia brought to the emergency room with complaints of generalized weakness for the last few days which is been getting worse and she also has developed cold symptoms on September 2 and tested positive on September 3 and since then patient was short of breath and mildly hypoxic about 86% and she took the more dose of the core with vaccine on February 2021 and nobody is sick in the home Patient denies any fever or chills chest pain vomiting diarrhea constipation body aches change in taste or smell.The patient began the hospital with positive infection ID consultation steroids nebulizer treatment andAntiviral medications per ID.
Information has been received from a medical assistant referring to multiple unspecified patients of unknown age and gender. The patients' medical history, concurrent condition and concomitant therapy were not provided. On unknown dates, the patients were vaccinated with doses of PEDVAXHIB (lot#, expiration date, dose and route not reported), which were improperly stored. No adverse effects were reported. Follow up information has been received from an other reporter on 07-JUL-2015 and refers to an 11 week old patient of unknown gender. On 02-JUN-2015, the patient was vaccinated with a dose of PEDVAHXIB lot # K016965, expiration date 20-JUL-2017. This is one of several reprots received from the same source. Additional information has been requested. Patient demographics, product and event details and narrative were updated.
Extreme pain in upper right arm. Reported 11-29-13 she couldn't reach her Dr till 12-2-13. Told her to seek medical advice 11-30 or 12-1 if pain was too severe to tolerate.
03/24/2021- ct called c/o new loss of taste/smell post vaccination, similar to when he had COVID infect 01/18/21. WPHL and Vault tests were both negative. Both sense of taste/smell have now returned.  03/26/21-Ct had 2nd dose.  04/05/21-Ct states he did fine after the 2nd dose, no problems at this time.  Unsure if loss of sense of taste/smell with 1st dose was related to the vaccine or if he is a COVID long hauler.
Information has been received from a nurse concerning unspecified patients of unknown age and gender. On unspecified dates, the multiple unspecified patients were administered with the dose of VARIVAX (Merck) (dose and route not provided, lot# L030160 with expire date of 11-AUG-2017), which was exposed to temperatures outside of the recommended range (Incorrect product storage) and was used within 3 months. No adverse effects have been reported. Additional information has been requested.
Baby found with SIDS in crib. Blue. No heart rate. Unresponsive.
First dose 29MAR2021 and Second dose 10May2021; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose 29MAR2021 and Second dose 10May2021) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose 29MAR2021 and Second dose 10May2021). On 10-May-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose 29MAR2021 and Second dose 10May2021) had resolved.            No concomitant medications were provided by reporter.  No treatment medications were provided by reporter.  The patient needed a vaccine replacement card.
9/10/02 Received vaccine at approximately 1:30PM. Within 30 minutes, patient started to break out with hives on chest, back, neck, arms, sneezing and flushed. Instructed to take to ER. 9/11/02 Took patient to PMD on 9/10/02. Hives disappearing. Instructed by PMD Benadryl and take to ER if worse.
pt recvd vax 23JUL93 & brought pt back to clinical room in near faint; Lips blue, verbally responsive to stimuli; BP 90/60, placed in trendelenberg position, cool packs to forehead;
One week later I developed a rash that extended beyond the arm, up my back and into my hair and ears.
Flat red rash on back seen initially. The next morning the rash was red, papular and itchy. New lesions on the face, neck, abdomen, legs.
Not to receive second dose in series until she recovers; "couldn't get out of bed"; doing a little better now; Practically immobile; could barely walk; achiness became worse and worse; "achy"; sore left arm; A spontaneous report was received from a consumer, concerning  herself a female patient of age 81years, who had received her first dose on (17-feb-2021) Moderna's COVID-19 experienced sore left arm , achy , achiness became worse , Difficulty in walking , immobile , Bedridden.  The patient's medical history include hypertension, COPD, hypothyroidism, and Fibromyalgia with pain, concomitant medication includes Levothroid, hydralazine, Bystolic, Savella, lisinopril, Ventolin Inhaler, Advair Inhaler and Oxygen at night was provided by reporter.  On 17-feb-2021 patient received her first dose of two planned doses of mRNA-1273 (lot number:028L20A) via intramuscular route for COVID-19 infection prophylaxis.  On same day she experienced soreness of left arm, 20Feb2021 she developed "achy" and stated that the achiness became worse and worse on 17Mar2021, she was "practically immobile" and "couldn't get out Of bed".  On 18 mar 2021 Patient consulted HCP and took ibuprofen (every 6th hourly) as treatment and her HCP advised her not to take second dose which was scheduled on 21 mar 2021.  Action taken with mRNA-1273 in response to the event was unknown.  The outcome of the event was resolving at the time of this reporting.; Reporter's Comments: This case concerns an 81 Y/O F with a serious unexpected event of immobile along with nonserious unexpected bedridden, gait disturbance, pre-existing condition improved, treatment noncompliance and expected vaccination site pain, myalgia.  Event onset on Day 4 after first dose mRNA-1273. Treated with ibuprofen. Events resolving. Based on current available information and temporal association between use of the product and the start date of the event, a causal relationship cannot be excluded.
Left upper deltoid red and swollen, hot to touch. (injection Td given on 02/04/05 in PM) Symptoms began 2/4/05 Friday night. Prednisone 40mg PO stat, Benadryl 25mg 2 hs on 2/7/05 not reported to nurse until 2/7/05.
Initially typical sore arm, low fever,  then worsened to higher fever, cough, pounding heart, trouble breathing, stiff neck and shoulder, chills
This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that there had been no power outages that would have impacted the Moderna vaccine. However, the reporter reiterates that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec 2021, Jan 2022, and Feb 2022. It was reported that the patients have been administered doses while the temperature excursion assessment was ongoing and reported that no adverse reactions were reported by any patients.
Booster administered less than 6months after primary series; towards the evening started not to feel well/ not feeling very well; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Booster administered less than 6months after primary series) and MALAISE (towards the evening started not to feel well/ not feeling very well) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058H21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer (1st dose, lot no-ER8733; thinks it was in the left arm) on 24-Oct-2021, Pfizer (2nd dose and lot no-ER8733; thinks it was in the left arm) on 15-Nov-2021. Past adverse reactions to the above products included No adverse event with Pfizer and Pfizer. Concurrent medical conditions included Type 2 diabetes mellitus (On medication), Headache (On medication) and Neuropathy (On medication).    On 30-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In December 2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MALAISE (towards the evening started not to feel well/ not feeling very well). On 30-Dec-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Booster administered less than 6months after primary series). On 30-Dec-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Booster administered less than 6months after primary series) had resolved. At the time of the report, MALAISE (towards the evening started not to feel well/ not feeling very well) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2021, Magnetic resonance imaging: results not provided MRI with contrast: results not provided, performed to scan all his body but focusing in the skull area.         It was reported that the patient did not have any side effect after the first and second doses from Pfizer.  The patient was suffering from Migraines since the early 70's right after he returned from.  He also stated that he takes a lot of medications for neuropathy, headaches, Type 2 diabetes and others.  Treatment information was not reported
Projectile vomiting and diarrhea within 2 hours of vaccines approximately 08. 30.11 continues with diarrhea.
1 day after Td vaccine patient states developed fatigue, muscle aching arms and legs with a couple cramps in calf muscles. Slight nausea.
Pharmacy Technician was administering the Moderna bivalent vaccine to a patient, and some of the vaccine spilled out of the syringe because the syringe needle was not appropriately attached.; syringe needle was not appropriately attached; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Pharmacy Technician was administering the Moderna bivalent vaccine to a patient, and some of the vaccine spilled out of the syringe because the syringe needle was not appropriately attached.), DEVICE CONNECTION ISSUE (syringe needle was not appropriately attached) and NO ADVERSE EVENT (No adverse event) in a 52-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (Pharmacy Technician was administering the Moderna bivalent vaccine to a patient, and some of the vaccine spilled out of the syringe because the syringe needle was not appropriately attached.), DEVICE CONNECTION ISSUE (syringe needle was not appropriately attached) and NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Pharmacy Technician was administering the Moderna bivalent vaccine to a patient, and some of the vaccine spilled out of the syringe because the syringe needle was not appropriately attached.), DEVICE CONNECTION ISSUE (syringe needle was not appropriately attached) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for ACCIDENTAL UNDERDOSE (Pharmacy Technician was administering the Moderna bivalent vaccine to a patient, and some of the vaccine spilled out of the syringe because the syringe needle was not appropriately attached.) and DEVICE CONNECTION ISSUE (syringe needle was not appropriately attached).    No concomitant medication was provided by the reporter.  It was reported that Pharmacy Technician was administering the Moderna bivalent vaccine to a patient, and some of the vaccine spilled out of the syringe because the syringe needle was not appropriately attached.  No treatment medication was provided by the reporter.   This case was linked to MOD-2022-674378 (Patient Link).
Approximately 12-24 hours after injection (6cm right tricep) swelling at site extending to right elbow, induration and warmness.  Treatment:  NSAIPS/ JLE/ SWETARON.
This case was reported by a consumer via call center representative and described the occurrence of pain in a male patient who received Shingrix for prophylaxis. On 18th September 2018, the patient received Shingrix. In September 2018, less than a week after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was unknown. It was unknown if the reporter considered the pain to be related to Shingrix. Additional details were provided as follows: The age at vaccination was not reported. The patient only stated that he had the injection and felt achy. An attempt was made to try to get more information for the report. The patient did not want to provide any more information, he just wanted an answer to his question about the vaccine.
The patient is a 12years old, who had the primary serious with pfizer COVID vaccination and the father made an appointment to vaccinate his son for a booster vaccintion with  Moderna COVID 19. This patient is not immunocompromised.  this patient should have received the Pfizer  booster per current guideline  since he is 12 years old.
I had a rash on most of my body and had turned into hives. Went to urgent care on 01/05/2022 and confirmed diagnosis with my GP on the next Monday (1/10/2022). Urgent care prescribed a cream, 5 day steroid pack and shot. Was advised alternate Benadryl and Zyrtec. At urgent care, only a physical was done, same with my GP. It took a couple of months but I do believe I have recovered.
I was diagnosed with Shingles on 04/04/2023. I thought I had a bug bite it was itching and spreading and became painful, I went to urgent care. I was prescribed VALTREX and fluocinonide; for my symptoms I was also prescribed NORCO for pain.
This spontaneous report was received from a medical assistant and refers to a two different patients of unknown age and gender. The patients' concurrent condition, medical history and concomitant medications were not reported. The reporter stated, that on unknown dates, 2 doses of improperly stored GARDASIL lot # K023432, expiration date: 18-JUN-2016 (dose, dose number, route of administration and anatomical location were not reported) were administered to two unspecified patients. There was no adverse effects reported. This is one of the several reports received from the same reporter. Additional information has been requested.
Arm soreness and fatigue the first evening post-vaccine. Around approximately 2300, I had chills, hot flashes, and a low fever (101) along with tachycardia, which lasted several hours. My heart rate was up to 150bpm at its highest while at rest. I took 800mg ibuprofen which seemed to help.  The next day I was very fatigued and nauseated. I started to have some gum soreness as well. The next day (2/21) I felt much better, but my lips felt very chapped along with some gum pain. As the days went on, the inside of my lips against my gums and teeth felt very raw and painful, and my lips became extremely chapped, while the corners of my mouth were cracked and painful as well.  On or around 2/24, I began to have some very sore spots on my soft palate, inner lips, and inside of my cheeks. They mostly became small white sores, except for my lips, which became very red with tiny blood spots just under the skin.  As of today (2/27), I still have sore gums, small sores on the inside of my mouth, several under my tongue, and the red sore spots on the inside of my lips.  It isn't life-threatening, but it is very uncomfortable, and makes eating and drinking painful. I don't feel the need to go to an ED or urgent care at this time, but will try to make an appointment with a GP as soon as I can.
This is an instance of breakthrough COVID-19 disease after which death occurred. The individual received Pfizer vaccine on 02/12/2021, 03/05/2021, and 10/25/2021. They tested positive for COVID-19 on 07/20/2022 at the nursing home at which they were a resident. They experienced an episode of acute respiratory arrest and were diagnosed with COVID-19 pneumonia. They died later on the same day,  on 07/20/2022.
Patient immediately became sweaty, dizzy,and experiencing hearing loss after receiving her first dose.Patient was seated on floor with elevated legs before she was wheeled back for observation. Patient was visually pale and sweaty.Patient denied any anxiousness before receiving her vaccine. Patient had vitals assessed and was given snacks and juice . Patient was reassessed after 15 minutes and reported feeling better and was sent home with parent. Patient and parent were advised to reach out to family doctor is any late onset of symptoms.